NCT06385522: A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System |
|
|
| Not yet recruiting | 1 | 37 | NA | BITR2101 | Boston Immune Technologies and Therapeutics | NHL, Cutaneous T Cell Lymphoma, Peripheral T-cell Lymphoma | 02/27 | 02/27 | | |
